WUXI XDC (02268) has released its interim results for the 2026 fiscal year, reporting revenue of approximately HK$3.701 billion, a year-on-year increase of 37.04%. Excluding the impact of foreign exchange fluctuations, the CER growth stood at 41.5%. Gross profit reached approximately HK$1.371 billion, up 40.6% year-on-year, while adjusted net profit attributable to shareholders of the company was approximately HK$1.027 billion, representing a 37.4% increase. Net profit attributable to shareholders of the company came in at approximately HK$819 million, up 9.87% year-on-year, with basic earnings per share of HK$0.65.

Excluding revenue from TOT BIOPHARM, WUXI XDC's standalone revenue reached HK$3.556 billion, with an AER growth of 31.7%. After adjusting for foreign exchange effects, the CER increase was 36.2%. During the reporting period, the company's standalone gross profit was approximately HK$1.337 billion, up 37.1% year-on-year, and its standalone gross margin improved from 36.1% to 37.6%. Standalone adjusted net profit grew to approximately HK$1.028 billion, up 37.5%, while the standalone adjusted net profit margin further rose from 27.7% to 28.9%.

According to the announcement, the revenue increase was primarily driven by (i) the sustained active development of the global ADC and broader bioconjugate drug market, which boosted both the number of clients and projects; (ii) the group's solid position as a leading ADC CRDMO service provider, which enhanced its market share; and (iii) the steady progression of projects into later stages, which typically generate higher contract values. During the reporting period, supported by the "Empower, Follow, and Win the Molecule" strategy, the group's ADC CRDMO business continued to grow. The group persisted in supporting comprehensive ADC and bioconjugate drug projects through its bioconjugate drug platform and global operations. In the reporting period, new project signings hit a historical high, reflecting the ongoing vitality of upstream R&D and providing further momentum for the sustained high-growth development of the bioconjugate drug industry.